Duramycins B and C, two new lanthionine containing antibiotics, have been isolated from Streptoverticillium strain R2075 and Streptomyces griseoluteus (R2107). The known antibiotics duramycin and cinnamycin were reisolated from Streptoverticillium hachijoense (DSM401 14) and Streptomyces longisporoflavus (DSM40165). The structures of these latter two compoundsshould be revised by changing amino acid residue 3 to glutamine and 17 to asparagine, respectively.
Fermentation
The fermentation of the 4 strains was carried out according to the following general scheme. Strain dependent variations are mentionedbelow.
General Fermentation Scheme
A well sporulated agar slant culture was used as a seed culture. The slant was washedwith 5ml of a 0.2-molar Soerensen phosphate buffer pH 7.
The resulting suspension was poured into a 500-ml Erlenmeyer flask with one baffle. It contained 100ml nutrient broth of the following composition: Soybean 2%, mannitol 2%. The pH was adjusted before sterilization to 8.2 with 1 n NaOH.The pH after sterilization was 7.4. The flask was shaken at 250rpm and 28°C for 48 hours. For a second preculture, three 2-liter Erlenmeyer flasks with four baffles, each containing 500ml of the soybean medium mentioned above, were inoculated with 25 ml each of the culture broth from the first preculture. The incubation was carried out at 120 rpm and 28°C for 48 hours.
The second flask preculture (1.5 liters) served as an inoculum for the 30 liters fermentation. Conditions:
50 liters stainless steel-fermenter containing 30 liters of the soybean medium, 600rpm, 28°C, 1
liter/liter/minute air throughput and 0.5 kp/cm2 pressure.
Strain Dependent Variations
A) R2075 (Streptoverticillium sp.) and R2107 (S. griseoluteus): Preculture medium: Oxo Lab Lemco 0.5%, Peptone C 0.5%, Casitone 0.3%, yeast extract 0.05%, glucose 2.2%, NaCl 0.15%, pH before sterilization: 7.0, after sterilization: 6.5.
Fermentation medium for strain R2075: Fishmeal 2.5%, malt extract 2.5%, glucose 0.5%, NH4NO3 0.05%, MgSO4 0.1%, CaCO3 0.5%, Ca3(PO4)2 0.3%, 1 ml/liter trace element solution, pH before and after sterilization: 6.5~6.7.
Trace element solution: ZnSO4-7H2O 0.3%, MnSO4-4H2O0.2%, CuSO4-5H2O 0.2%, FeSO4-7H2O 0.3%, CoCl2-6H2O 0.5%, (NH4)6Mo7O24 H2O 0.2%, H3BO3 0.2%.
Fermentation medium for strain R2107: As with R2075 but 2.5% cotton seed meal instead offishmeal. Optimal production levels were reached after 168 hours for R2075 and after 132 hours for R2107. B) DSM401 14 (S. hachijoense): Fermentation at 450rpm instead of 600rpm; optimal production titers after about 72 hours. C) DSM40165 (S. longisporoflavus): Preculture conditions: For the second preculture the same conditions as for the first one were used. The inoculum was 5%.
Fermentation conditions: 10 liters glass fermenter with 5 liters soybean medium, 28°C, 800rpm, 1 liter/liter/minute air, no overpressure. Optimal production after about 72 hours.
Isolation Procedure
In general, aqueous solvents were removed in the following way: First the organic component was distilled in vacuo. The remaining solution was then lyophilized.
Isolation of Duramycin (1) The whole culture broth was filtered, the culture solution extracted with equal volumes of ethyl acetate and the organic phase discarded. The aq phase was concentrated in vacuo and then adsorbed on Amberlite XAD-1180 (9 liters). The resin was washed consecutively with water (0.4 bed volumes), aq 20% methanol (1 bed volume) and aq 70% 2-propanol (2 bed volumes). The 2-propanol eluate was concentrated on a Rotavap to a dark concentrate (2 liters) which was extracted with 1 liter of butanol. The organic phase was washed with a sodium chloride solution (10%, 2 x 250ml) and yielded 6.6g of a brownish residue
The authors wish to thank Dr. R. M. Kroppenstedt (DSM, Braunschweig) for the taxonomical definition of strains. upon drying. The material was further purified by partition chromatography4) on a Sephadex G-25 column (coarse, 9 liters), using butanol-water-acetic acid (4 : 5 : 1) as the partitioning medium. The stationary phase was saturated with 2 bed volumes of lower phase before equilibration with 1 bed volume of the upper phase (water saturated BuOH). After sample loading in 90ml of upper phase compound 1 was eluted with the upper phase (320ml/hour). The active fractions from 3.4 to 5.4 liters were collected to give 0.68g of a colorless residue. This material was dissolved in 50% aq 2-propanol (2.5% w/v) and finally purified to homogeneity on a reversed phase column (Antec UPC12, 10/mi as the stationary phase; 30 x 170mm; H2O-MeOH-TFA(28 : 72 : 0.1); 7.5ml/minute; backpressure 30bar; sample load45mg/run; Rt 22 minutes) to yield 220mg of pure peptide 1 on drying (25% overall recovery). Optionally, aliquots of the TFAsalt were converted to the acetate salt by ion exchange chromatography on DE-52 (Whatman; AcO~) using 0.05m ammonium acetate buffer at pH 4.5. (2) The whole culture broth (5 liters) was filtered and the culture solution extracted with ethyl acetate. The aq phase was concentrated in vacuo and adsorbed on Amberlite XAD-1180as described above for the isolation of duramycin. The resin was washed stepwise with water, aq methanol (20%) and 2-propanol (70%), yielding 2.5 g of a colored lyophilizate.
Isolation of Cinnamycin
The powder was dissolved in aq AcOH (0.1 n, 100ml) and 100 ml of BuOH. The aq phase was extracted twice with the samevolume of BuOH. The combinedorganic phases were concentrated in vacuo and lyophilized (880 mg). The material was fractionated by partition chromatography on Sephadex G-25 (fine, 2.5 x 70cm). The elution was carried out with the upper phase 
Isolation of Duramycin B (3)
The whole culture broth was filtered, concentrated in vacuo and then lyophilized yielding 371 g of a solid residue. The powder was triturated three times with methanol (1 1 liters total) and the solvent discarded leaving 100g of a brownish residue. An aliquot (10.9g) was suspended in water (200ml), acidified with TCA (30ml of a 30% solution) at 0°C, stirred for 10 minutes and centrifuged (10 minutes, 10,000rpm). The clear supernatant was adjusted to pH3 (1n NaOH)and applied on a reversed-phase column (LiChroprep RP-18, 15~25//m; 40 x 250mm; gradient elution with water-acetonitrile-TFA (100 : 0 : 0.1 to 60 : 40 : 0.1) in 30 minutes; 30ml/minute; Rt 38 minutes; 220nm) to give 3 as a colorless powder (342mg, 29% overall recovery).
Isolation of Duramycin C (4)
The whole culture broth of two 30 liters fermenters was filtered yielding 42 liters of filtrate. This was applied on a column with Amberlite XAD-1180 (20-50 mesh; 15x 135cm; 25 liters; 37 liters/hour). Fraction 1 (acetonitrile -water (20 : 80); 50 liters; 50 liters/hour) contained almost no active compound and was discarded. Fraction 2 (acetonitrile -water (30 : 70): 50 liters; 25 liters/hour) was concentrated in vacuo to 3 liters and extracted three times with butanol (400ml) whereby the organic phase was discarded. The aq phase was then lyophilized to yield 10.5 g of a brown powder. The lyophilizate was suspended in water (200ml) and centrifuged (5 minutes, 12,000rpm). The brown precipitate (3.51 g) contained the desired material in 75% purity. Additional material was obtained by addition of TCA(16ml of a 30% solution) to the supernatant and centrifugation (5 minutes, 12,000rpm) to give a second precipitate (1.87g; 20% purity). Both solids were finally chromatographed on a preparative reversed-phase column (LiChroprep RP-18, 15-25/im; conically shaped Biichi column, 300ml; solvent A: water-TFA (100 : 0.1); solvent B: acetonitrile-water-TFA (80:20:0.07); gradient from 10% B to 40% B in 4 minutes then to 50% B in 30 minutes; 30ml/minute; sample dissolved in 17ml H2O-acetonitrile (90 : 10) and adjusted to pH 8 with 1 n NH3; Rt 24 minutes; 220nm; 15 runs) to give 4 as an almost colorless powder (2.81 g, 47% overall recovery).
Determination of the Chirality of the AminoAcids The hydrolyzates (6n HCI, 12 hours at 105°C) of compounds 1 to 4 were esterified with 2-propanol (2 hours at 105°C; acidified with 1.2n HCI) and then acetylated with trifluoroacetic anhydride (2 hours, room temperature). The derivatized amino acids were resolved by capillary gas chromatography on a chiral stationary phase (Chirasil-Val)5). The usual amino acids except arginine were identified by comparison with commercialstandards. mm>-Lanthioninewas recognized as the main peak in a commercial mixture of the D-, l-and meso-form6). DW/*reo2-Hydroxyaspartic acid (Vega Biochemicals, Tucson, Az.) racemizes partially during the derivatization procedure and elutes in four peaks: The threo isomers before the erythro and the D-form earlier than the l (a generally accepted rule for this stationary phase). The derivatized amino acids of compounds 1 to 4 gave a peak coeluting with L-erj^/zr0-2-hydroxyaspartic acid. The chirality of arginine in 2 and 3 was established by separating the two enantiomers on Crownpak CR (Daicel, Tokyo, Japan), a HPLCcolumn containing a chiral crown ether. The amino acids of 2 and 3 (hydrolyzed with 6n HCI, 12 hours at 105°C) showed a strong peak coeluting with L-arginine, but none at the Rt of the D-form (4x 150mm, aq 0.01n HC1O4, pH=2.05; temperature 5°C; 0.4ml/minute; The separation of all four lantibiotics7) is shown in Fig. 1 . It is noteworthy that a very low concentration of acetonitrile is essential at the beginning of the gradient profile to separate 1, 2 and 3. This is an effect frequently observed with peptides and is probably due to conformational changes of the molecule on the hydrophobic stationary phase which are influenced by the solvent polarity.
Trisulfoxide of Duramycin B (5) A solution ofduramycin B (100mg) and H2O2 (30^1; 30%) in 0.5ml acetic acid was stirred for 90 minutes at room temperature, then kept at 4°C overnight. The mixture was diluted with 0.5 ml H2O, lyophilized and the residue applied on a preparative Assay for Inhibition of Phospholipase A2 Activity Phospholipase A2 was extracted from human polymorphonuclear (PMN)leukocytes by treatment with acid and high salt concentration, followed by dialysis, as described previously8). Humansynovial fluid obtained by biopsy was centrifuged and the enzymein the cell-free supernatant was used without further treatment. Both enzymes were assayed as described8* by incubation for 1 hour at 37°C in the presence of 0.1 m Tris-HCl buffer pH 7.0, l.OmM CaCl2 and 2.5 x 108 [l-14C]oleate-labeled autoclaved Escherichia coli (5 nmol phospholipid) as substrate. Enzyme concentrations were adjusted to produce a hydrolysis of the substrate of 10~15%, which is within the linear range of the assay. The reaction was stopped by extraction with Dole reagent. Released [l-14C]oleic acid was separated from substrate on silicic acid columns and determined by radiometry. IC50 values were determined graphically from plots of percent inhibition versus log concentration of inhibitors. The values reported are the mean±standarderror of 3~5 independent assays.
Results and Discussion
Structure and Physico-chemical Properties Duramycin, cinnamycin and several other antibiotics of this family have been known for thirty years9).
They contain the unusual amino acids lanthionine (abbreviation: ala-S-ala) and methyllanthionine (abbreviation: abu-S-ala) with a stable thioether bridge. Although a partial structure of duramycin was already published by Gross et al. in 19761O) , the first complete structure of a memberof this class, namely ancovenin, was presented by Shiba's group only 4 years ago11*. Amino acid analysis of the four metabolites presented in this paper also showed the presence of these unusual amino acids suggesting that they belong to the growing family of lantibiotics. The product isolated from S. hachijoense (DSM401 14) was shown to be identical to duramycin by the following results: 1) Acid hydrolysis gave the same amino acid composition as published earlier10* (Table 1) .
2) The FAB-MSof the isolated material 1 and duramycin from our antibiotics collection were identical.
3) The two compounds were esterified with methanol and gave again a matching m/z in the Identified by gas phase sequencing. Identified by *H NMR. Identified by GC-MSof the TV-TFA-isopropyl ester derivative.
Duramycin, leucopeptin and cinnamycin are from our antibiotics collection. Duramycin (1) Cinnamycin ( FAB-MS. 4) Both antibiotics eluted at the same Rt in the HPLC(see Fig. 1 ). Using the same method it was demonstrated that strain DSM40165 (S. longisporoflavus) produces cinnamycin12). Moreover another previously unidentified antibiotic namely leucopeptin1, a peptide isolated by Kondo et al. in 196413) , was proven to be identical to duramycin by the same procedures described above.
In Table 1 the amino acid compositions of some duramycin type antibiotics are compared. Cinnamycin (2) has the same amino acid composition as Ro 09-019814), also called lanthiopeptin15). In the first patent application16) this antibiotic was reported to contain D-phenylalanine residues. However,in a more recent publication, the presence of the L-form of this amino acid could be unambiguously established17).
In duramycin B (3) one of the three phenylalanines found in 2 is replaced by leucine. Preliminary structural data on leucinamycin18) indicate a close homology to 3. Leucinamycin appears to contain four glutamic acids, whereas 3 has only a single glutamine.
In contrast to compounds 1 to 3 duramycin C (4) has no basic amino acid residue, but it contains tyrosine and tryptophane which give rise to the characteristic UVspectrum of 4. Therefore, its amino acid composition is similar to ancovenin. But important differences are seen in the unusual amino acids. In ancovenin the formation of the lysinoalanine ring from 2,3-didehydroalanine and lysine has not taken place. The close structural resemblance between duramycin C and ancovenin suggests a common biosynthetic pathway with ring closure at a very late stage. Formation of lysinoalanine during workup of 4 can be excluded, since the HPLCretention time of 4 in the crude fermentation broth and as a pure compound is identical.
The physico-chemical properties of compounds 1 to 4 are compiled in Table 2 . For the first time we present FAB-MSdata of duramycin and cinnamycin. The mass difference of m/z 28 between the methyl esters and the parent compoundssuggests that they all have only two acidic functions. Therefore the structures of duramycin and cinnamycin showing four acidic groups as reported by Gross12) have to be revised. Sequencing data of duramycin and cinnamycin reveal glutamine (and not glutamic acid) in position 3 and asparagine instead of aspartic acid in step 17. Based on all our results cinnamycin 2 is most likely identical to Ro 09-0198. The proposed structures of the new compounds 3 and 4 are shown in Fig. 2 . Fig. 3 presents a general structural skeleton for all duramycin type antibiotics. The thioether bridges as assigned for ancovenin11} and Ro 09-019814'15) are assumed to be commonfor all. Further work on the structure of compounds1 to 4 is in progress.
The CD spectra of all duramycin antibiotics look very similar showing a characteristic negative Duramycin (1) ellipticity at 208 nm. The strong molar ellipticity suggests a very rigid conformation. The pattern displays no similarity to the reference spectra of proteins in a-helix, /?-sheet or randomcoil conformation19).
To get some insight into the structure-activity relationship the trisulfoxide of duramycin B (5) was prepared by peracetic acid oxidation. The identity of the product was established by FAB-MS.According to 1H NMRit consisted of a mixture of diastereoisomers.
Biological Activity
Duramycins B and C are potent inhibitors of human phospholipase A2. As shown in Table 3 both compounds inhibited the enzyme from PMNleukocytes and synovial fluid with IC50 in the micromolar range. Similar activity was observed with the chemically related antibiotics duramycin and cinnamycin. Surprisingly, the trisulfoxide of duramycin B (5) did not inhibit at concentrations up to 30^mol/liter indicating that at least one of the thioether groups is essential for biological activity. Further studies on the mechanism of action and the effect of these compounds on other phospholipases are in progress and will be reported elsewhere.
As shown in Table 4 , duramycins B and C exhibit only a weak antibacterial activity against Bacillus subtHis. Their antimicrobial spectrum is therefore very similar to Ro 09-0198, which was also only active against the same highly sensitive Gram-positive test strain (MIC O.yS^g/ml)16^1 411 
